Zai Lab (ZLAB) is trading up at $25.62 (+5.30%), as of the latest quote. It operates in the Health Care sector.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | $129.0K | $13.0M | $49.0M | $144.3M | $215.0M | $266.7M | $399.0M | $460.2M |
| Growth (year over year) | — | — | — | +9965.9% | +277.0% | +194.8% | +49.0% | +24.0% | +49.6% | +15.3% |
| Gross profit | — | — | $85.9K | $9.24M | $32.2M | $92.1M | $141.0M | $170.9M | $251.9M | $269.6M |
| Gross margin | — | — | 66.6% | 71.1% | 65.8% | 63.8% | 65.6% | 64.1% | 63.1% | 58.6% |
| Operating income | −$38.5M | −$51.4M | −$141.8M | −$203.2M | −$301.8M | −$700.1M | −$404.4M | −$366.6M | −$282.1M | −$229.4M |
| Operating margin | — | — | −109897.7% | −1564.9% | −616.4% | −485.1% | −188.0% | −137.4% | −70.7% | −49.9% |
| Net income | −$37.5M | −$50.4M | −$139.1M | −$195.1M | −$268.9M | −$704.5M | −$443.3M | −$334.6M | −$257.1M | −$175.5M |
| Net margin | — | — | −107810.1% | −1502.3% | −549.3% | −488.2% | −206.1% | −125.5% | −64.4% | −38.1% |
| EPS (diluted) | −$3.97 | −$2.32 | −$2.64 | −$3.03 | −$0.35 | −$0.76 | −$0.46 | −$0.35 | −$0.26 | −$0.16 |
| Balance sheet | ||||||||||
| Cash and equivalents | $83.9M | $229.7M | $63.0M | $75.9M | $442.1M | $964.1M | $1.01B | $790.2M | $449.7M | $679.6M |
| Total assets | $88.9M | $249.6M | $302.0M | $355.2M | $1.30B | $1.61B | $1.22B | $1.04B | $1.19B | $1.17B |
| Total liabilities | $5.95M | $14.5M | $50.9M | $60.5M | $128.3M | $230.0M | $174.5M | $240.2M | $344.9M | $456.9M |
| Shareholders' equity | −$51.6M | $235.2M | $251.1M | $294.7M | $1.17B | $1.38B | $1.05B | $796.1M | $840.9M | $715.5M |
| Cash flow | ||||||||||
| Operating cash flow | −$32.2M | −$32.4M | −$97.5M | −$191.0M | −$216.1M | −$549.2M | −$367.6M | −$198.2M | −$214.9M | −$150.8M |
| Capital expenditure | $2.22M | $9.10M | $10.0M | $6.04M | $10.1M | $18.3M | $24.6M | $7.21M | $5.66M | $8.10M |
| Free cash flow | −$34.4M | −$41.5M | −$107.6M | −$197.0M | −$226.2M | −$567.5M | −$392.2M | −$205.4M | −$220.5M | −$158.9M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $102.3M | $109.1M | $106.5M | $110.0M | $116.1M | $127.6M | $99.6M | $106.3M |
| Growth (year over year) | +47.7% | +65.7% | +22.2% | +9.4% | +13.5% | +17.0% | −6.5% | −3.3% |
| Gross profit | $65.7M | $67.3M | $68.0M | $67.0M | $69.3M | $65.3M | $61.3M | $58.1M |
| Gross margin | 64.2% | 61.7% | 63.9% | 60.9% | 59.7% | 51.2% | 61.5% | 54.7% |
| Operating income | −$67.9M | −$67.9M | −$56.3M | −$54.9M | −$48.8M | −$69.4M | −$69.4M | −$76.5M |
| Operating margin | −66.4% | −62.2% | −52.9% | −49.9% | −42.1% | −54.4% | −69.7% | −71.9% |
| Net income | −$41.7M | −$81.7M | −$48.4M | −$40.7M | −$36.0M | −$50.4M | −$51.0M | −$50.8M |
| Net margin | −40.7% | −74.9% | −45.5% | −37.0% | −31.0% | −39.5% | −51.2% | −47.8% |
| EPS (diluted) | −$0.04 | −$0.09 | −$0.04 | −$0.04 | −$0.03 | −$0.05 | −$0.05 | −$0.05 |
| Balance sheet | ||||||||
| Cash and equivalents | $616.1M | $449.7M | $757.3M | $732.2M | $717.2M | $679.6M | $651.3M | $607.5M |
| Total assets | $985.3M | $1.19B | $1.17B | $1.16B | $1.16B | $1.17B | $1.10B | $1.07B |
| Total liabilities | $317.7M | $344.9M | $362.6M | $372.4M | $399.0M | $456.9M | $433.8M | $467.8M |
| Shareholders' equity | $667.7M | $840.9M | $810.8M | $791.7M | $759.9M | $715.5M | $662.0M | $607.0M |
| Cash flow | ||||||||
| Operating cash flow | −$26.8M | −$55.8M | −$61.7M | −$31.0M | −$32.0M | −$26.0M | −$11.9M | −$63.4M |
| Capital expenditure | $1.34M | $2.60M | $1.53M | $2.88M | $3.00M | $677.0K | $1.20M | $1.31M |
| Free cash flow | −$28.2M | −$58.4M | −$63.2M | −$33.9M | −$35.0M | −$26.7M | −$13.1M | −$64.7M |
From Zai Lab's 10-K, 10-Q, 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Zai Lab in our feed yet.